What Are the Qualifications for Weight Loss Injections in the UK?

Which BMI and health conditions actually qualify you?

The licensed threshold for both Mounjaro (tirzepatide) and Wegovy (semaglutide) is a BMI of 30 or above. If your BMI sits between 27 and 29.9, you can still qualify provided you have at least one weight-related comorbidity. The conditions that count include type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea, and cardiovascular disease, among others.

There is one thing worth clearing up early: BMI is a starting point, not a pass mark. A prescriber considers the whole picture, your current medications, your medical history, and whether anything in that history makes treatment inadvisable. Someone with a BMI of 34 and a history of pancreatitis, for example, would need a careful conversation with a prescriber before any medicine is considered. The NHS medicines page for tirzepatide sets out the licensed contraindications in detail.

For some ethnic backgrounds, the BMI thresholds used in UK clinical practice sit 2.5 kg/m² lower than the headline figures. This reflects evidence that health risks associated with excess weight appear at lower BMI values in South Asian, Chinese, Middle Eastern, Black African and African-Caribbean populations. If that applies to you, it is worth discussing with a prescriber, lower thresholds can bring you into eligibility you might not otherwise expect.

You can explore the full qualifying criteria for weight loss injections in more detail to see how the conditions and BMI thresholds interact in practice.

How does NHS eligibility differ from private eligibility?

This is where the confusion tends to sit for most people, and it is understandable. The NHS does not simply offer treatment to everyone who meets the licensed criteria, it follows NICE guidance, which applies stricter requirements.

For tirzepatide, NICE recommends NHS access for adults with a BMI of 35 or above and at least one qualifying weight-related condition. For semaglutide via the NHS, NICE guidance similarly sets the bar at BMI 35 or above in most cases, and only within a specialist weight management service. NHS England is rolling out access in phases: from June 2025, the first cohort covered adults with a BMI of 40 or above plus four or more of a defined list of conditions; a second cohort (BMI 35 to 39.9 with four or more conditions) became eligible from June 2026. Waiting lists for specialist services remain long in many areas.

Private treatment through a regulated online pharmacy follows the licensed criteria rather than NICE's NHS-specific thresholds. That means many adults who don't yet meet NHS eligibility can access treatment privately, provided a prescriber judges it clinically appropriate. The personal eligibility checker walks through how this works in practice. For context on what private treatment costs and what a transparent price includes, the treatment overview page is the right place to look.

What medical history can affect your qualification?

Certain conditions mean weight loss injections are not recommended, regardless of BMI. A history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) is a contraindication for both Mounjaro and Wegovy. A personal or close family history of those conditions is something a prescriber will ask about directly.

Pregnancy, breastfeeding, and actively trying to conceive are all situations in which these medicines are not recommended. That applies to both injections currently licensed for weight management in the UK. Under-18s are also outside the licensed indication.

Severe gastrointestinal conditions, certain kidney or liver problems, and some combinations of existing medications may also affect suitability, your prescriber will work through these as part of the assessment. If you are considering a weight loss medication injection, the overview of how these medicines work and what to expect if you do qualify is a useful place to start.

One category of medicines worth flagging separately: women taking oral contraceptives who start tirzepatide are advised to use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after any dose increase, because tirzepatide can slow gastric emptying in a way that may affect how oral contraceptives are absorbed. NHS England's guidance on weight management injections covers this point clearly. It is the kind of practical detail that a thorough prescriber will raise with you, and one that a quick online questionnaire alone might miss.

Does prediabetes or type 2 diabetes change the picture?

Both conditions appear on the list of qualifying weight-related comorbidities, so having either strengthens the case for treatment under both the private licensed criteria and NHS guidance. Tirzepatide holds a separate UK licence for type 2 diabetes management, which means it has a particularly well-evidenced profile in that population. There is a dedicated look at how these medicines sit alongside prediabetes and weight loss injections if that is your situation.

For people with type 2 diabetes, it is also worth noting that semaglutide exists in a diabetes-specific form (Ozempic) that is licensed for blood sugar management rather than weight loss. The weight loss injection is Wegovy, which uses the same molecule at a higher dose and under a different licence. If you want to understand which medicine is which, including the weight loss injections medication names you are likely to encounter and what distinguishes them, the guide to weight loss injection medication for diabetes separates these clearly.

Our clinical team reviews every consultation individually, checking medical history, concurrent medicines and the specific details of each patient's situation. A prescriber is always the person making the call, not an automated system. If you have questions about whether your circumstances qualify you, the most straightforward next step is a free consultation, there is no obligation, and you will get a clear answer.